Skip to main content
SpringerLink
Log in

Pathophysiology and Risk Stratification in Cardiovascular Diseases and NAFLD

  • Chapter
  • First Online:
Essentials of Non-Alcoholic Fatty Liver Disease

  • 376 Accesses

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a complex multisystem disease in which genetic predisposition, obesity, visceral fat, insulin resistance, lipoprotein dysfunction, and gut dysbiosis determine a chronic inflammatory response associated with endothelial dysfunction, procoagulant status, and increased cardiovascular risk. NAFLD is associated with an increased risk of ischemic heart disease in direct relation to liver fibrosis severity. NAFLD is an independent cardiovascular risk factor, and it should be included in specific cardiovascular risk scores.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25(24):3009–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. In: Engin AB, Engin A, editors. Obesity and lipotoxicity (Advances in experimental medicine and biology; vol. 960). Cham: Springer International Publishing; 2017. p. 277–304. https://doi.org/10.1007/978-3-319-48382-5_12.

    Chapter  Google Scholar 

  4. Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20(1):57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol. 2014;34(9):1820–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Petta S, Argano C, Colomba D, Cammà C, Di Marco V, Cabibi D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62(4):928–33.

    Article  PubMed  Google Scholar 

  7. Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging. 2015;8(1):e001979.

    Article  PubMed  Google Scholar 

  8. Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. In: Terjung R, editor. Comprehensive physiology. 1st ed. New York: Wiley; 2017. p. 1–22. https://doi.org/10.1002/cphy.c170012.

    Chapter  Google Scholar 

  9. Vergani L. Fatty acids and effects on in vitro and in vivo models of liver steatosis. Curr Med Chem. 2019;26(19):3439–56.

    Article  CAS  PubMed  Google Scholar 

  10. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fabbrini E, Magkos F. Hepatic steatosis as a marker of metabolic dysfunction. Nutrients. 2015;7(6):4995–5019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11(9):802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596–607.

    Article  CAS  PubMed  Google Scholar 

  14. Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep. 2021;3(6):100346.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhou F, Zhou J, Wang W, Zhang X, Ji Y, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119–33.

    Article  PubMed  Google Scholar 

  16. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut–liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95.

    Article  CAS  PubMed  Google Scholar 

  17. Fatima S, Hu X, Gong RH, Huang C, Chen M, Wong HLX, et al. Palmitic acid is an intracellular signaling molecule involved in disease development. Cell Mol Life Sci. 2019;76(13):2547–57.

    Article  CAS  PubMed  Google Scholar 

  18. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:1–16.

    Article  Google Scholar 

  19. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ—linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–93.

    Article  PubMed  Google Scholar 

  20. Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711–24.

    Article  CAS  PubMed  Google Scholar 

  21. Vairappan B. Endothelial dysfunction in cirrhosis: role of inflammation and oxidative stress. World J Hepatol. 2015;7(3):443.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–79.

    Article  CAS  PubMed  Google Scholar 

  23. Trépo E, Valenti L. Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020;72(6):1196–209.

    Article  PubMed  Google Scholar 

  24. Sharma D, Mandal P. NAFLD: genetics and its clinical implications. Clin Res Hepatol Gastroenterol. 2022;46(9):102003.

    Article  CAS  PubMed  Google Scholar 

  25. Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The protection conferred by HSD17B13 rs72613567 polymorphism on risk of steatohepatitis and fibrosis may be limited to selected subgroups of patients with NAFLD. Clin Transl Gastroenterol. 2021;12(9):e00400.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2020;63(2):253–60.

    Article  CAS  PubMed  Google Scholar 

  27. Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, et al. Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham Heart study. Clin Gastroenterol Hepatol. 2019;17(6):1157–1164.e4.

    Article  CAS  PubMed  Google Scholar 

  28. Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, et al. Role of microbiota-derived metabolites in alcoholic and non-alcoholic fatty liver diseases. Int J Mol Sci. 2021;23(1):426.

    Article  PubMed  PubMed Central  Google Scholar 

  29. He Y, Hwang S, Ahmed YA, Feng D, Li N, Ribeiro M, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol. 2021;18(1):18–37.

    Article  CAS  PubMed  Google Scholar 

  30. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509–20.

    Article  CAS  PubMed  Google Scholar 

  31. Stefan N, Häring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9(3):144–52.

    Article  CAS  PubMed  Google Scholar 

  32. Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, et al. Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review. Cell. 2022;11(16):2511.

    Article  CAS  Google Scholar 

  33. Boga S, Alkim H, Koksal AR, Bayram M, Ozguven MBY, Ergun M, et al. Increased plasma levels of asymmetric dimethylarginine in nonalcoholic fatty liver disease: relation with insulin resistance, inflammation, and liver histology. J Investig Med. 2015;63(7):871–7.

    Article  CAS  PubMed  Google Scholar 

  34. Li D, Xie P, Zhao S, Zhao J, Yao Y, Zhao Y, et al. Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD. Biochem Biophys Res Commun. 2021;555:54–60.

    Article  CAS  PubMed  Google Scholar 

  35. Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, et al. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol. 2019;71(6):1193–205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61(1):148–54.

    Article  CAS  PubMed  Google Scholar 

  37. Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020;21(15):5214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–37.

    Article  PubMed  Google Scholar 

  39. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.

    Article  PubMed  Google Scholar 

  40. Miele L, Alberelli MA, Martini M, Liguori A, Marrone G, Cocomazzi A, et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res. 2020;2020:003.

    Google Scholar 

  41. Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki PV, Szilveszter B, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. Clin Gastroenterol Hepatol. 2021;19(7):1480–1488.e14.

    Article  PubMed  Google Scholar 

  42. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13.

    Article  PubMed  Google Scholar 

  43. Loosen S, Luedde M, Demir M, Luedde T, Kostev K, Roderburg C. An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137,842 patients with and without chronic liver disease. Eur J Gastroenterol Hepatol. 2022;34(6):717–23.

    Article  CAS  PubMed  Google Scholar 

  44. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

    Irina Girleanu & Stefan Chiriac

  2. Institute of Gastroenterology and Hepatology, “Saint Spiridon” University Hospital, Iasi, Romania

    Irina Girleanu & Stefan Chiriac

Authors
  1. Irina Girleanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Chiriac
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Anca Trifan

  2. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Carol Stanciu

  3. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Cristina Muzica

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Girleanu, I., Chiriac, S. (2023). Pathophysiology and Risk Stratification in Cardiovascular Diseases and NAFLD. In: Trifan, A., Stanciu, C., Muzica, C. (eds) Essentials of Non-Alcoholic Fatty Liver Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-33548-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-33548-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-33547-1

  • Online ISBN: 978-3-031-33548-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation